Fundraising FoxAlgeta
Unicorn exit · $2.9Bacquired by Bayer4 known investors
Find your way into Algeta
Acquired by Bayer AG December 2013 · $2.9B ($2.9 billion (48% premium to pre-announcement share price)) · source ↗
Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.
Investors · 4
Advent Life Scienceslisted by Advent Life SciencesLondon
How we know: Advent Life Sciences's portfolio page · Not right? Tell us
Birk Venturelisted by Birk VentureOslo
How we know: Birk Venture's portfolio page · Not right? Tell us
AbingworthreportedLondon · $15M – $30M
How we know: funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Algeta do?
- Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.
- Who are Algeta's investors?
- Algeta's investors include Advent Life Sciences, Birk Venture, HealthCap, Abingworth.
- Who acquired Algeta?
- Algeta was acquired by Bayer.